Patient characteristics
| . | Prior-HTN (n = 118) . | De novo HTN (n = 78) . | Entire cohort (N = 196) . |
|---|---|---|---|
| Diagnosis | |||
| CLL/SLL | 112 (94.9%) | 72 (92.3%) | 184 (93.9%) |
| MCL | 3 (2.5%) | 3 (3.8%) | 6 (3.1%) |
| Other | 3 (2.5%) | 3 (3.8%) | 6 (3.1%) |
| BTKi type | |||
| Ibrutinib | 101 (85.6%) | 75 (96.2%) | 176 (89.8%) |
| Acalabrutinib | 9 (7.6%) | 1 (1.3%) | 10 (5.1%) |
| Other | 8 (6.8%) | 2 (2.6%) | 10 (5.1%) |
| Current treatment line | |||
| 1 | 57 (48.3%) | 39 (50.0%) | 96 (49.0%) |
| 2 | 32 (27.1%) | 18 (23.1%) | 50 (25.5%) |
| ≥3 | 29 (24.6%) | 21 (26.9%) | 50 (25.5%) |
| Age, median (range), y | 67.5 (42.0-88.0) | 65.5 (37.0-87.0) | 67 (37.0-88.0) |
| Race | |||
| Caucasian | 100 (92.6%) | 73 (97.3%) | 173 (94.5%) |
| Other | 8 (7.4%) | 2 (2.7%) | 10 (5.5%) |
| Missing | 10 | 3 | 13 |
| Sex | |||
| Female | 34 (29.3%) | 20 (25.6%) | 54 (27.8%) |
| Male | 82 (70.7%) | 58 (74.4%) | 140 (72.2%) |
| History of DM | 25 (21.2%) | 9 (11.5%) | 34 (17.3%) |
| History of CAD | 5 (4.2%) | 0 (0.0%) | 5 (2.6%) |
| History of CKD | 2 | 0 | 2 |
| BTKi on a clinical trial | 29 (24.6%) | 17 (21.8%) | 46 (23.5%) |
| BTKi dose reduction | |||
| No | 84 (71.2%) | 59 (75.6%) | 143 (73.0%) |
| Yes, for HTN | 7 (5.9%) | 2 (2.6%) | 9 (4.6%) |
| Yes, for other reasons | 27 (22.9%) | 17 (21.8%) | 44 (22.4%) |
| Time to BTKi dose reduction; median days (range) | 382.5 (0.0-1651.0) | 365.0 (0.0-1574.0) | 366.0 (0.0-1651.0) |
| Switch to other BTKi | |||
| No | 111 (94.1%) | 73 (93.6%) | 184 (93.9%) |
| Yes, for HTN | 3 (2.5%) | 2 (2.6%) | 5 (2.6%) |
| Yes, for other reasons | 4 (3.4%) | 3 (3.8%) | 7 (3.6%) |
| Time to switching to other BTKi; median days (range) | 308.0 (85.0-1631.0) | 1445.0 (386.0-3775.0) | 777.0 (85.0-3775.0) |
| BTKi stopped | |||
| No | 92 (78.0%) | 59 (75.6%) | 151 (77.0%) |
| Yes, for HTN | 26 (22.0%) | 18 (23.1%) | 44 (22.4%) |
| Yes, for other reasons | 0 (0.0%) | 1 (1.3%) | 1 (0.5%) |
| . | Prior-HTN (n = 118) . | De novo HTN (n = 78) . | Entire cohort (N = 196) . |
|---|---|---|---|
| Diagnosis | |||
| CLL/SLL | 112 (94.9%) | 72 (92.3%) | 184 (93.9%) |
| MCL | 3 (2.5%) | 3 (3.8%) | 6 (3.1%) |
| Other | 3 (2.5%) | 3 (3.8%) | 6 (3.1%) |
| BTKi type | |||
| Ibrutinib | 101 (85.6%) | 75 (96.2%) | 176 (89.8%) |
| Acalabrutinib | 9 (7.6%) | 1 (1.3%) | 10 (5.1%) |
| Other | 8 (6.8%) | 2 (2.6%) | 10 (5.1%) |
| Current treatment line | |||
| 1 | 57 (48.3%) | 39 (50.0%) | 96 (49.0%) |
| 2 | 32 (27.1%) | 18 (23.1%) | 50 (25.5%) |
| ≥3 | 29 (24.6%) | 21 (26.9%) | 50 (25.5%) |
| Age, median (range), y | 67.5 (42.0-88.0) | 65.5 (37.0-87.0) | 67 (37.0-88.0) |
| Race | |||
| Caucasian | 100 (92.6%) | 73 (97.3%) | 173 (94.5%) |
| Other | 8 (7.4%) | 2 (2.7%) | 10 (5.5%) |
| Missing | 10 | 3 | 13 |
| Sex | |||
| Female | 34 (29.3%) | 20 (25.6%) | 54 (27.8%) |
| Male | 82 (70.7%) | 58 (74.4%) | 140 (72.2%) |
| History of DM | 25 (21.2%) | 9 (11.5%) | 34 (17.3%) |
| History of CAD | 5 (4.2%) | 0 (0.0%) | 5 (2.6%) |
| History of CKD | 2 | 0 | 2 |
| BTKi on a clinical trial | 29 (24.6%) | 17 (21.8%) | 46 (23.5%) |
| BTKi dose reduction | |||
| No | 84 (71.2%) | 59 (75.6%) | 143 (73.0%) |
| Yes, for HTN | 7 (5.9%) | 2 (2.6%) | 9 (4.6%) |
| Yes, for other reasons | 27 (22.9%) | 17 (21.8%) | 44 (22.4%) |
| Time to BTKi dose reduction; median days (range) | 382.5 (0.0-1651.0) | 365.0 (0.0-1574.0) | 366.0 (0.0-1651.0) |
| Switch to other BTKi | |||
| No | 111 (94.1%) | 73 (93.6%) | 184 (93.9%) |
| Yes, for HTN | 3 (2.5%) | 2 (2.6%) | 5 (2.6%) |
| Yes, for other reasons | 4 (3.4%) | 3 (3.8%) | 7 (3.6%) |
| Time to switching to other BTKi; median days (range) | 308.0 (85.0-1631.0) | 1445.0 (386.0-3775.0) | 777.0 (85.0-3775.0) |
| BTKi stopped | |||
| No | 92 (78.0%) | 59 (75.6%) | 151 (77.0%) |
| Yes, for HTN | 26 (22.0%) | 18 (23.1%) | 44 (22.4%) |
| Yes, for other reasons | 0 (0.0%) | 1 (1.3%) | 1 (0.5%) |
CAD, coronary artery disease; CKD, chronic kidney disease; DM, diabetes mellitus; SLL, small lymphocytic lymphoma.